Reduced short-term variation following antenatal administration of betamethasone: Is reduced fetal size a predisposing factor? by Ghi, Tullio et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology 216 (2017) 74–78Full Length Article
Reduced short-term variation following antenatal administration of
betamethasone: Is reduced fetal size a predisposing factor?
Tullio Ghia,*, Andrea Dall’Astaa, Gabriele Sacconeb, Federica Bellussic, Tiziana Fruscaa,
Pasquale Martinellib, Gianluigi Piluc, Nicola Rizzoc
aObstetrics and Gynecology Unit, University of Parma, Parma, Italy
bDepartment of Neuroscience, Reproductive Sciences, and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy
cDepartment of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy
A R T I C L E I N F O
Article history:
Received 3 March 2017
Received in revised form 5 July 2017







A B S T R A C T
Objective: To assess the association between fetal size and the incidence of reduced short-term variability
(STV) following bethametasone administration for fetal lung maturity.
Study design: This was a retrospective, multicenter, cohort study conducted in two Tertiary University
Units. Only uncomplicated singleton pregnancies admitted for threatened preterm labor between 26 and
34 weeks and submitted to betamethasone for fetal lung maturity were included. Delivery occurring
within 72 h from betamethasone administration represented criteria for exclusion. Computerized
cardiotocography was carried out on a daily basis. Cases were identiﬁed by persistently reduced STV,
deﬁned as <5th percentile for gestational age and lasting for at least 72 h after the ﬁrst dose of
betamethasone. The primary outcome was estimated fetal weight (EFW) at ultrasound in fetuses with
normal and in those with persistently reduced STV. Pregnancy outcomes were also evaluated.
Results: Persistently reduced STV occurred in 33/405 of the included patients (8.1%). Compared to women
with normal STV, those with persistently reduced STV had signiﬁcantly lower EFW (1472  435 vs
1812  532 g, p 0.04), lower birthweight (2353  635 vs 2857  796 g, p < 0.01) and earlier gestational age
at delivery (35.1  4.2 vs 37.3  2.4 weeks, p < 0.01), whereas all the other variables including gestational
age on admission were comparable.
Conclusions: Reduced STV following maternal betamethasone administration among appropriately
grown fetuses seems to correlate with lower fetal size. Furthermore, fetuses with such abnormal
response to steroids seem to carry a higher risk of perinatal complications, including lower birthweight
and earlier gestational age at delivery.
© 2017 Published by Elsevier Ireland Ltd.
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A course of antenatal steroids between 24 weeks and 34
weeks + 6 days is universally recommended in pregnant women at
risk for impending delivery as it has been consistently demon-
strated to decrease the occurrence of perinatal mortality and
morbidity in preterm infants [1,2].
Betamethasone (BMT) has shown to produce some transient
effects including a reduction in body and breathing movements
and a decrease in the short-term variability (STV) observed with
computerized cardiotocography (cCTG) [3–7]. In a small propor-
tion of cases such profound depressive effects on the fetal heart* Corresponding author at: Department of Obstetrics and Gynecology, University
of Parma, Via Antonio Gramsci 14, 43126 Parma, Italy.
E-mail address: tullio.ghi@unipr.it (T. Ghi).
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0301-2115/© 2017 Published by Elsevier Ireland Ltd.rate variability may persist up to 3 days after its administration [4],
leading to inappropriate clinical decisions if they are misinter-
preted as a sign of brain hypoxia.
It is still unclear why only some fetuses exhibit a reduced heart
rate variability following steroids administration [6].
The aim of this study was two-fold: to assess the incidence of
reduced STV following BMT administration for fetal lung maturity
in a group of fetuses at risk of preterm delivery and identify which
factors may predispose to this abnormal response.
Methods
Study design and study population
This was a retrospective, multicenter, cohort study. Clinical
records of all consecutive women admitted for threatened preterm
labor (PTL) to the Department of Obstetrics of the University
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Reproductive Science, University of Naples Federico II (Naples,
Italy) from January 2009 to December 2014 were collected in a
dedicated merged database.
All charts recorded in the database were reviewed. All variables
reported were collected for all the subjects included in the study.
All patients were aged 18 or above and submitted to BMT
administration for fetal lung maturity between 26 and 34 weeks of
gestation. In this group, two doses of BMT 12 mg were adminis-
tered intramuscularly 24 hours (h)apart as recommended [1].
Threatened PTL was deﬁned by the presence of regular uterine
contractions (2–3 every 10 min) associated with early cervical
changes at clinical examination (effacement and/or dilatation
>1cm). As per internal protocol of the Centres involved, tocolysis
was administered in all women submitted to RDS prophylaxis for
threatened PTL. Cervical length measurement at transvaginal
ultrasound or result of the ﬁbronectin test were not considered for
the purpose of this study.
Exclusion criteria were multiple pregnancy, congenital anoma-
lies, intrauterine growth restriction (IUGR), deﬁned by abdominal
circumference (AC) or ultrasound estimated fetal weight (EFW)
<10th centile with or without umbilical artery Doppler pulsatility
index >95th percentile, any preexisting medical condition
including hypertensive disorders, chronic drug consumption and
diabetes mellitus or gestational diabetes, abnormal CTG and/or
cCTG on admission and delivery within 72 h from steroids
administration. Women with premature rupture of membranes
(PROM) and antepartum haemorrhage (APH) were also excluded.
Management
All women included in the study received daily cCTG assessing
fetal heart rate and STV starting from admission. Algorithm for
cCTG were based on Dawes/Redman antepartum CTG analysis by
using Sonicaid (Sonicaid Obstetric Solutions, Huntleigh) [8,9]. The
recordings were at least 45 min in duration. STV values were
recorded for each assessment. cCTGs were performed on a daily
basis in the morning. We considered “day 1 cCTG” only those
performed at least 12 h after BMT administration.
The study cohort was divided in two groups according to the
STV ﬁndings: group A (cases) showed persistently reduced STV
deﬁned by values below the 5th percentile for gestational age [10]
following BMT administration and lasting up to 72 h after the 1st
dose; group B (controls) STV >5th percentile after the administra-
tion of BMT or <5th percentile for less than 72 h after ﬁrst dose.
Ultrasound assessment of fetal weight was performed in all
cases within 3 days from admission and accordingly to the local
reference charts [11].
Outcomes
A comparison of demographics, clinical characteristics and
pregnancy outcomes was performed between cases with persis-
tently reduced vs those with normal STV following BMT
administration. Due to its retrospective design, the study did
not affect the clinical management of the patients, which was
based upon the judgement of the attending physician. As this was a
retrospective analysis of routinely collected anonymized clinical
data, no ethical committee approval was necessary according to
national regulations.
The primary outcome was mean EFW at ultrasound. Secondary
outcomes were mean birthweight in grams, prevalence of small for
gestational age (SGA) at birth, gestational age at delivery, mode of
delivery. SGA neonates were deﬁned as those whose birthweight
was below the 10th centile according to the national neonatalcharts [12]. Neonatal outcomes, including Apgar score at 5 min,
umbilical artery pH and base excess at delivery were also recorded.
Statistical analysis
Statistical analysis was performed using Statistical Package for
Social Sciences (SPSS) v. 19.0 (IBM Inc., Armonk, NY, USA). Data
were shown as mean  standard deviation or as number (percent-
age). Categorical variables were compared using the Chi-square or
Fisher exact test. Between-group comparison of continuous
variables was undertaken using T-test for parametric analysis.
Standardized scores were created to assess Z-score for birth weight
and ultrasound EFW.
Two sided p-values were calculated and p values <0.05 were
considered as statistically signiﬁcant. The study was performed
following the STROBE guidelines [13].
Results
Over the study period, 4120 women were admitted between 26
and 34 weeks for PTL and received prophylactic BMT. Of them, 405
(9.8%) met the inclusion criteria and were included in the study
(Fig. 1).
Mean gestational age at admission and at delivery was
31.5  2.4 weeks and 36.2  3.1 weeks, respectively. Overall, 33
fetuses (8.1%) showed STV below the 5th centile following BMT
administration and lasting up to 72 h whereas 372 had normal or
temporarily reduced STV <5th percentile lasting <72 h. No
signiﬁcant differences were noted in terms of maternal demo-
graphics between the two groups (Table 1).
Women with persistently reduced STV following BMT admin-
istration had signiﬁcantly lower EFW and EFW Z-score on
admission (1472 + 435 vs 1812 + 532 g, p 0.04 and 0.002  0.411
vs 0.401 0.612, p 0.04, respectively) and lower birthweight and
birthweight Z-score (2353 + 635 vs 2857 + 796 g, p < 0.01 and
0.463  0.470 vs 0.103  0.315, p 0.03, respectively) compared
with those with normal STV showed. The incidence of SGA at birth
was signiﬁcantly higher (18.2% vs 7.8%, p 0.04) and the gestational
age at delivery was lower (35.1 + 4.2 vs 37.3 + 2.4, p < 0.01) among
fetuses who showed persistently reduced STV following steroids
administration (Table 2).
Discussion
Our study conﬁrmed that a reduced STV is observed at cCTG in a
small proportion of fetuses (8.1%) following antenatal BMT
administration for fetal lung maturity. Interestingly, despite all
fetuses of this series were of appropriate size for gestational age at
inclusion, those who presented the reduced STV following steroids
appeared signiﬁcantly smaller than those with normal STV. In
addition, pregnancy outcome appeared to be different in those
with reduced STV after steroids compared to controls, as they were
delivered a couple of weeks earlier and had a smaller birthweight
and a higher incidence of SGA neonates.
The transient depressive effect of antenatal betamethasone on
fetal heart rate variability has been largely documented [3–7].
Available data have shown that a decrease in the STV within 72 h
from the ﬁrst dose is not related to acid–base changes [14] but
might be due to a direct effect of betamethasone on glucocorticoid
receptors. Such receptors are believed to be present in the
brainstem and other areas of the human brain involved in the
control of the fetal heart activity [4,5,15,16].
The STV reduction due to BMT administration seems to be
inversely related to the gestational age at steroids administration
[14,17]. In our group of fetuses with reduced STV the gestational
age at BMT exposure was not different compared with those with
Fig. 1. Flow chart (according to STROBE guidelines) for inclusion of cases. BMT, Bethametasone; HDP, hypertensive disorder of the pregnancy; DM, diabetes mellitus; SGA, small for
gestational age; IUGR, intrauterine growth restriction; PPROM, premature preterm rupture of the membranes; APH, antepartum haemorrhage; CTG, cardiotocography.
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smaller weight noted in the former group.
This observation leads us to speculate that the depressive effect
of BMT on fetal brain may be favored in cases of slightly reduced
placental reserve. As recently proposed, early stage placental
insufﬁciency does not lead to fetal smallness but may inducerelevant haemodynamic changes. More in details, fetal biometry at
ultrasound may remain within the normal range but the weight
percentile is smaller compared to previous measurements and
blood ﬂow redistribution may be noted [18]. Recently, a reduced
cerebroplacental ratio has been described during the third
trimester in normal sized fetuses with subtle placental
Table 2
Primary and secondary outcomes.





EFW 1472  435 1812  532 0.04
EFW Z-score 0.002  0.411 0.401  0.612 0.04
Birthweight 2353  635 2857  796 < 0.01
Birthweight Z-score 0.463  0.470 0.103  0.315 0.03
GA at delivery 35.1  4.2 37.3  2.4 < 0.01
Mode of delivery
SVD 18 (54.5%) 222 (59.7%) 0.74
OVD 1 (3.1%) 6 (1.6%)
CD 14 (42.4%) 144 (38.7%)
Vaginal delivery n = 19 n = 228 0.53
Spontaneous onset 16 (84.2%) 178 (78.1%)
Induction of labor 3 (15.8%) 50 (21.9%)
CD n = 14 n = 144 0.29
Planned 11 (78.6%) 93 (65.6%)
Emergency 3 (21.4%) 51 (34.4%)
SGA 6 (18.2%) 29 (7.8%) 0.04
APGAR at 5 min 9.0  0.4 9.0  0.6 0.95
Umbilical artery pH 7.23  0.04 7.28  0.08 0.06
Base excess 5.8  1.2 5.5  2.0 0.21
Data presented as number (percentage) or as mean  standard deviation. Boldface
data, statistically signiﬁcant.
GA, gestational age; EFW, ultrasound estimated fetal weight; SVD, spontaneous
vaginal delivery; OVD, operative vaginal delivery; CD, cesarean delivery; SGA, small
for gestational age.
Primary and secondary outcomes in cases with reduced short-term variability (STV)
after bethametasone administration and controls with normal STV.
a According to Snijders et al., Fetal Diagn Ther 1990 [10].
Table 1






Age 32.8  4.9 33.6  5.3 0.22
BMI 24.3  2.6 24.9  3.1 0.37
Ethnicity
Caucasian 25 (75.8%) 301 (80.9%) 0.13
Non-Caucasian 8 (24.2%) 71 (19.1%)
Nulliparous 13 (39.4%) 143 (38.4%) 0.74
GA at admission 31.8  4.2 31.2  3.4 0.81
STV
Before steroids 11.2  1.1 11.4  3.2 0.61
24 h 6.3  2.2 9.8  3.1 <0.01
48 h 4.4  1.4 8.8  2.7 <0.01
72 h 6.1  3.1 8.7  3.3 0.03
Data are presented as number (percentage) or as mean  standard deviation.
Boldface data, statistically signiﬁcant.
GA, gestational age; STV, short-term variability; BMI, body mass index.
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signiﬁcantly higher [19,20]. Some Authors previously described a
higher frequency of reduced STV after BMT in fetuses with cerebral
vasodilatation at Doppler ultrasound [21]. Unfortunately, in our
study group the fetal cerebral ﬂow was not assessed and we are
unable to conﬁrm if Doppler ﬁndings witnessed blood ﬂow
redistribution and reduced placental reserve in those fetuses with
reduced STV, whose weight percentile was in the lower range of
normality.
On the other hand, in the same group of fetuses with transiently
depressed STV after steroids, a signiﬁcantly lower birthweight and
a higher incidence of SGA neonates was noted. This may lead us to
envisage that the abnormal CNS response at steroids could be
looked not as an incidental ﬁnding but as an early sign of reduced
placental reserve in apparently normal sized fetuses and, at the
same time, as a useful predictor of late onset placental dysfunction
and lower birthweight requiring a modiﬁed obstetric manage-
ment.On this basis, we suggest that whenever an apparently
appropriately grown fetus exposed to BMT exhibits a transiently
reduced STV a comprehensive maternal and fetal Doppler
ultrasound should be performed in order to spot early signs of
placental dysfunction. Furthermore, we propose that if spontane-
ous preterm delivery does not occur, these fetuses should be
incorporated in a program of intensive antepartum surveillance
since their risk of late onset placental insufﬁciency may be
increased.
Some limitations need to be acknowledged in this study,
including the small number of cases with reduced STV and its
retrospective design. Furthermore, having excluded those patients
with a true threatened PTL who delivered within 72 h from
admission, we could only assess the depressive effects on the fetal
heart rate variability in those fetuses who remained undelivered
and could not generalize our results to all cases exposed to
antenatal steroids. In this study, as widely reported [22], only a
small proportion of patients admitted with PTL actually delivered
shortly following BMT administration. Most women with threat-
ened PTL have minimal cervical dilation on manual exam, and over
60% do not deliver preterm [23]. Finally, the selection of only
normally grown fetuses at inclusion may introduce a bias by the
insufﬁciency of methods to perform this selection and discriminate
between IUGR and non IUGR fetuses. On the other hand, inclusion
of pregnancies complicated by IUGR would introduce a confounder
which may impact on the aim and the results of the study, as
chronic hypoxia per se may be cause of fetal behavioral changes
including a reduced STV at cCTG.
Despite these limitations, we have observed that among
apparently normal sized fetuses a depressive effect of antenatal
steroids is more likely if the weight percentile is in the lower range
and this effect may herald an increased risk for late onset placental
insufﬁciency and lower birthweight. This original ﬁnding is worthy
to be reported and conﬁrmed prospectively in a larger study where
a comprehensive Doppler assessment following antenatal admin-
istration is included.
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